Advertisement
Canada markets close in 2 hours 6 minutes
  • S&P/TSX

    21,887.00
    -124.72 (-0.57%)
     
  • S&P 500

    5,079.36
    +8.81 (+0.17%)
     
  • DOW

    38,525.49
    +21.80 (+0.06%)
     
  • CAD/USD

    0.7300
    -0.0021 (-0.28%)
     
  • CRUDE OIL

    82.66
    -0.70 (-0.84%)
     
  • Bitcoin CAD

    88,876.95
    -2,624.46 (-2.87%)
     
  • CMC Crypto 200

    1,405.64
    -18.46 (-1.30%)
     
  • GOLD FUTURES

    2,336.40
    -5.70 (-0.24%)
     
  • RUSSELL 2000

    1,993.67
    -8.98 (-0.45%)
     
  • 10-Yr Bond

    4.6560
    +0.0580 (+1.26%)
     
  • NASDAQ

    15,751.82
    +55.18 (+0.35%)
     
  • VOLATILITY

    15.77
    +0.08 (+0.51%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6821
    -0.0015 (-0.22%)
     

Stocks in play: Prometic Life Sciences Inc.

Announced new long-term clinical data from its pivotal Phase 2/3 trial of Ryplazymℱ (Plasminogen IV) ...

Announced new long-term clinical data from its pivotal Phase 2/3 trial of Ryplazymℱ (Plasminogen IV) in patients with congenital plasminogen deficiency. The data demonstrates that in 10 patients treated with RyplazymTM for a total of 48 weeks, there was no recurrence of lesions and no safety or tolerability issues observed related to this longer-term dosing. Prometic Life Sciences Inc.